Lupin is currently trading at Rs. 779.25, up by 4.30 points or 0.55% from its previous closing of Rs. 774.95 on the BSE.
The scrip opened at Rs. 776.35 and has touched a high and low of Rs. 780.60 and Rs. 770.10 respectively. So far 11755 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 887.70 on 04-Feb-2019 and a 52 week low of Rs. 646.20 on 07-Oct-2019.
Last one week high and low of the scrip stood at Rs. 780.10 and Rs. 759.05 respectively. The current market cap of the company is Rs. 35034.60 crore.
The promoters holding in the company stood at 46.96%, while Institutions and Non-Institutions held 38.99% and 14.05% respectively.
Lupin’s Ankleshwar facility has won the gold award at the 9th annual conference on quality management, organised by the American Society for Quality (ASQ) at Ahmedabad on November 22, 2019. The nomination case study submitted for this award summarised the transformation project to improve the yield and quality of company’s Cefadroxil products. This is the fourth consecutive year that Lupin's Ankleshwar facility has won the Gold Award from the American Society for Quality.
This year company's nomination highlighted the key outcomes of its ‘Cefadroxil Yield and Quality Improvement’ project, in the past three years, the company won the award for projects that focused on ethambutol yield improvement (2018), 7AE yield improvement (2017) and 7ACCA yield improvement (2016).
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Check out your favorite Offers touch the link and read some best Services – Stock Cash Tips
No comments:
Post a Comment